CN112638937B - 聚乙二醇化的破伤风神经毒素和张力减退的治疗 - Google Patents
聚乙二醇化的破伤风神经毒素和张力减退的治疗 Download PDFInfo
- Publication number
- CN112638937B CN112638937B CN201980057158.3A CN201980057158A CN112638937B CN 112638937 B CN112638937 B CN 112638937B CN 201980057158 A CN201980057158 A CN 201980057158A CN 112638937 B CN112638937 B CN 112638937B
- Authority
- CN
- China
- Prior art keywords
- ile
- asn
- leu
- tent
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Detergent Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510841942.0A CN120661638A (zh) | 2018-07-31 | 2019-07-30 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018902779 | 2018-07-31 | ||
| AU2018902779A AU2018902779A0 (en) | 2018-07-31 | Composition and method | |
| PCT/AU2019/050793 WO2020024002A1 (en) | 2018-07-31 | 2019-07-30 | Pegylated tetanus neurotoxins and treatment of hypotonia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510841942.0A Division CN120661638A (zh) | 2018-07-31 | 2019-07-30 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112638937A CN112638937A (zh) | 2021-04-09 |
| CN112638937B true CN112638937B (zh) | 2025-06-17 |
Family
ID=69230503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980057158.3A Active CN112638937B (zh) | 2018-07-31 | 2019-07-30 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
| CN202510841942.0A Pending CN120661638A (zh) | 2018-07-31 | 2019-07-30 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510841942.0A Pending CN120661638A (zh) | 2018-07-31 | 2019-07-30 | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12697379B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4134133A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2021533201A (cg-RX-API-DMAC7.html) |
| CN (2) | CN112638937B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019315327B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021001520A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3108079C (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021001181A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ772266A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202100646SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020024002A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4417131A1 (en) | 2023-02-15 | 2024-08-21 | Canon Medical Systems Corporation | X-ray diagnostic apparatus, x-ray diagnostic system, and x-ray diagnostic method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019118974A2 (en) * | 2017-12-15 | 2019-06-20 | The Medical College Of Wisconsin, Inc. | Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| AU2003200441B2 (en) * | 1998-04-29 | 2006-07-06 | Allergan, Inc. | Compositions and methods for modulating neural sprouting |
| GB9914861D0 (en) | 1999-06-25 | 1999-08-25 | Imperial College | Tetanus toxin polypeptides |
| MXPA03000014A (es) | 2000-06-28 | 2004-09-13 | Ira Sanders | Metodos para utilizar con fines beneficiosos toxina tetanica en animales. |
| WO2003000193A2 (en) | 2001-06-21 | 2003-01-03 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
| US20040013687A1 (en) | 2002-05-31 | 2004-01-22 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
| WO2008024879A1 (en) * | 2006-08-25 | 2008-02-28 | University Of Maryland, Baltimore | Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment |
| WO2010124998A1 (en) * | 2009-04-27 | 2010-11-04 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities |
| WO2011115483A1 (en) | 2010-03-15 | 2011-09-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Peptides, conjugates and method for increasing immunogenicity of a vaccine |
| EP3164149A1 (en) | 2014-07-02 | 2017-05-10 | Spherium Biomed S.L. | Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc) |
| MX2018002183A (es) * | 2015-08-27 | 2018-05-28 | Harvard College | Composiciones y metodos para tratamiento del dolor. |
| CN106692963B (zh) * | 2016-12-28 | 2020-12-22 | 中国人民解放军军事医学科学院生物工程研究所 | 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗 |
| WO2021155427A1 (en) * | 2020-02-03 | 2021-08-12 | Snoretox Pty Ltd | Composition and method |
-
2019
- 2019-07-30 MX MX2021001181A patent/MX2021001181A/es unknown
- 2019-07-30 CN CN201980057158.3A patent/CN112638937B/zh active Active
- 2019-07-30 JP JP2021529491A patent/JP2021533201A/ja active Pending
- 2019-07-30 CA CA3108079A patent/CA3108079C/en active Active
- 2019-07-30 CA CA3167665A patent/CA3167665A1/en active Pending
- 2019-07-30 EP EP22183027.6A patent/EP4134133A1/en active Pending
- 2019-07-30 NZ NZ772266A patent/NZ772266A/en unknown
- 2019-07-30 BR BR112021001520-5A patent/BR112021001520A2/pt unknown
- 2019-07-30 US US17/261,975 patent/US12697379B2/en active Active
- 2019-07-30 AU AU2019315327A patent/AU2019315327B2/en active Active
- 2019-07-30 EP EP19843147.0A patent/EP3830110A4/en active Pending
- 2019-07-30 CN CN202510841942.0A patent/CN120661638A/zh active Pending
- 2019-07-30 SG SG11202100646SA patent/SG11202100646SA/en unknown
- 2019-07-30 WO PCT/AU2019/050793 patent/WO2020024002A1/en not_active Ceased
-
2023
- 2023-11-20 JP JP2023196375A patent/JP7786745B2/ja active Active
-
2025
- 2025-11-25 JP JP2025203043A patent/JP2026026159A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019118974A2 (en) * | 2017-12-15 | 2019-06-20 | The Medical College Of Wisconsin, Inc. | Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021001181A (es) | 2021-04-19 |
| CA3108079A1 (en) | 2020-02-06 |
| EP3830110A4 (en) | 2022-03-02 |
| JP2021533201A (ja) | 2021-12-02 |
| CA3108079C (en) | 2023-10-10 |
| CA3167665A1 (en) | 2020-02-06 |
| WO2020024002A1 (en) | 2020-02-06 |
| CN120661638A (zh) | 2025-09-19 |
| NZ772266A (en) | 2022-09-30 |
| JP2026026159A (ja) | 2026-02-16 |
| EP3830110A1 (en) | 2021-06-09 |
| US12697379B2 (en) | 2026-08-04 |
| AU2019315327B2 (en) | 2024-05-09 |
| JP2024014975A (ja) | 2024-02-01 |
| AU2019315327A1 (en) | 2021-02-11 |
| CN112638937A (zh) | 2021-04-09 |
| US20210353724A1 (en) | 2021-11-18 |
| EP4134133A1 (en) | 2023-02-15 |
| BR112021001520A2 (pt) | 2021-04-20 |
| KR20210040407A (ko) | 2021-04-13 |
| SG11202100646SA (en) | 2021-02-25 |
| NZ789962A (en) | 2025-07-25 |
| JP7786745B2 (ja) | 2025-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102550926B1 (ko) | 이중 항체 구축물을 발현하는 aav를 포함하는 조성물 및 이들의 용도 | |
| CN111269925B (zh) | 携带自杀基因的robo1 car-nk细胞及其制备方法和应用 | |
| CN113980991B (zh) | 大肠杆菌-芽孢杆菌穿梭质粒载体及其构建方法和应用 | |
| KR20240032025A (ko) | 내이의 세포 유형-특이적 유전자 발현을 위한 조성물 및 방법 | |
| CN112779292B (zh) | 构建瘦肉率高、生长快且抗蓝耳病和系列腹泻病的优质猪核移植供体细胞的方法及其应用 | |
| CN112725344B (zh) | 密码子优化的smn1基因、腺相关病毒表达质粒及基因药物 | |
| KR102679920B1 (ko) | 모노머형 스트렙타비딘을 발현하는 균주 및 비오틴화된 화합물을 포함하는 암 세포 표적용 조성물 | |
| CN111304141B (zh) | 产n-乙酰-5-羟色胺的重组大肠杆菌及其构建方法和应用 | |
| CN112877362A (zh) | 构建高繁殖力、抗蓝耳病和系列腹泻病的优质猪核移植供体细胞的基因编辑系统及其应用 | |
| CN112638937A (zh) | 聚乙二醇化的破伤风神经毒素和张力减退的治疗 | |
| CN112522258A (zh) | Il2rg基因和ada基因联合敲除的重组细胞及其在制备免疫缺陷猪模型中的应用 | |
| KR102679923B1 (ko) | 모노머형 스트렙타비딘을 발현하기 위한 컨스트럭트 | |
| CN112680444B (zh) | 用于oca2基因突变的crispr系统及其在构建白化病克隆猪核供体细胞中的应用 | |
| CN111500629B (zh) | 一种高表达层粘连蛋白-511变体的方法及其应用 | |
| CN112342231A (zh) | 一种不耐热ung融合蛋白的重组载体及表达纯化方法 | |
| CN109022487A (zh) | 一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物 | |
| CN112522309A (zh) | 重症免疫缺陷猪源重组细胞及其制备方法和试剂盒 | |
| CN114107390B (zh) | 一种用于表达抗体IgG1的rAAV载体及其应用 | |
| CN112522313B (zh) | 用于构建TPH2基因突变的抑郁症克隆猪核供体细胞的CRISPR/Cas9系统 | |
| KR102774499B1 (ko) | 예비표적화 단백질을 발현하는 균주를 포함하는 생체 내 미생물 추적 플랫폼 | |
| CN112813101B (zh) | 一种构建瘦肉率高、生长快的优质猪核移植供体细胞的基因编辑系统及其应用 | |
| CN114958758B (zh) | 一种乳腺癌模型猪的构建方法及应用 | |
| CN112795566A (zh) | 用于构建骨质疏松症克隆猪核供体细胞系的opg基因编辑系统及其应用 | |
| CN112575033B (zh) | Crispr系统及其在构建scn1a基因突变的癫痫性脑病克隆猪核供体细胞中的应用 | |
| CN112680453B (zh) | Crispr系统及其在构建stxbp1突变的癫痫性脑病克隆猪核供体细胞中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TG01 | Patent term adjustment | ||
| TG01 | Patent term adjustment |
Free format text: NEW EXPIRY DATE: 20391115 |